HomeInsightsStock Comparison

Alivus Life Sciences Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Alivus Life Sciences Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Last Updated on: Jul 08, 2025

Key Highlights

  • The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1010 as of 08 Jul 11:11.
  • The P/E Ratio of Alivus Life Sciences Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 7.5 on March 2020 to 0 on March 2024 . This represents a CAGR of -100.00% over 5 years.
  • The Market Cap of Alivus Life Sciences Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 5814 crore on March 2020 to ₹ 27019 crore on March 2024 . This represents a CAGR of 35.97% over 5 years.
  • The revenue of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Glenmark Pharmaceuticals Ltd for the Mar '25 is ₹ 3267 crore as compare to the Dec '24 revenue of ₹ 3418 crore. This represent the decline of -4.41%.
  • The ebitda of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Glenmark Pharmaceuticals Ltd for the Mar '25 is ₹ 199.89 crore as compare to the Dec '24 ebitda of ₹ 631.36 crore. This represent the decline of -68.34%.
  • The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 173.13 crore to ₹ 4.38 crore over 8 quarters. This represents a CAGR of -84.09% .
  • The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 58.56 % on March 2024 . This represents a CAGR of -1.60% over 3 yearsThe Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 5.21 % on March 2020 to 1.37 % on March 2024 . This represents a CAGR of -23.44% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alivus Life Sciences Ltd

  • Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
  • The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Glenmark Pharmaceuticals Ltd

  • Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
  • The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
  • It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
  • The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
  • Its branded generics business has a significant presence in markets across emerging economies including India.

Alivus Life Sciences Ltd News Hub

News

Board of Alivus Life Sciences recommends final dividend

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting h...

Read more

16 May 2025 09:27

News

Alivus Life Sciences to hold board meeting

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

09 May 2025 10:57

News

Alivus Life Sciences allots 92,096 equity shares under ESOS

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Conseq...

Read more

30 Apr 2025 19:38

News

Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBIT...

Read more

23 Jan 2025 15:01

News

Alivus Life Sciences Ltd leads gainers in 'A' group

Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are amon...

Read more

21 Jan 2025 12:00

News

Glenmark Life Sciences renamed as Alivus Life Sciences

Glenmark Life Sciences announced its change of identity to Alivus Life Sciences, marking a...

Read more

20 Jan 2025 10:18

Glenmark Pharmaceuticals Ltd News Hub

News

Glenmark Pharmaceuticals Ltd spurts 1.6%, rises for fifth straight session

Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoti...

Read more

04 Jul 2025 13:00

News

Glenmark Pharmaceuticals Ltd up for third straight session

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quotin...

Read more

02 Jul 2025 13:05

News

Glenmark Pharmaceuticals launches TEVIMBRA' in India

Glenmark Pharmaceuticals (Glenmark) launched TEVIMBRA' (tislelizumab) in India following t...

Read more

24 Jun 2025 10:53

News

Glenmark pharma's US facility receives five observations after USFDA GMP inspection

According to a regulatory filing by the company, the USFDA conducted a good manufacturing ...

Read more

18 Jun 2025 09:51

News

Glenmark Pharmaceuticals Ltd soars 0.98%, rises for fifth straight session

Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoti...

Read more

11 Jun 2025 13:00

News

Glenmark receives DCGI approval to launch oncology drug BRUKINSA in India

Glenmark Pharmaceuticals has announced the upcoming launch of zanubrutinib in India follow...

Read more

09 Jun 2025 11:04

SWOT Analysis Of Glenmark Pharmaceuticals Ltd

Strength

4

S

Weakness

2

W

Opportunity

1

O

Threats

1

T

SWOT Analysis Of Alivus Life Sciences Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

0

T

BlinkX Score for Glenmark Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alivus Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alivus Life Sciences Ltd and Glenmark Pharmaceuticals Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Glenmark Pharmaceuticals Ltd?

Market cap of Alivus Life Sciences Ltd is 12,529 Cr while Market cap of Glenmark Pharmaceuticals Ltd is 52,555 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Glenmark Pharmaceuticals Ltd?

The stock performance of Alivus Life Sciences Ltd and Glenmark Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Glenmark Pharmaceuticals Ltd?

As of July 8, 2025, the Alivus Life Sciences Ltd stock price is INR ₹1021.75. On the other hand, Glenmark Pharmaceuticals Ltd stock price is INR ₹1862.35.

How do dividend payouts of Alivus Life Sciences Ltd and Glenmark Pharmaceuticals Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Glenmark Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions